# Healthcare Growth Stocks Fall as Rising Treasury Yields Dampen Market Risk Appetite

- URL: https://stocks.freetheai.org/news/healthcare-growth-stocks-fall-as-rising-treasury-yields-dampen-market-risk-34a4a0
- Published: 2026-10-16T20:20:43Z
- Category: markets; sentiment: bearish; impact: medium
- Symbols: [NASDAQ:PACB](https://stocks.freetheai.org/symbols/NASDAQ-PACB), [NASDAQ:MRNA](https://stocks.freetheai.org/symbols/NASDAQ-MRNA), [NASDAQ:MYGN](https://stocks.freetheai.org/symbols/NASDAQ-MYGN), [NASDAQ:AZTA](https://stocks.freetheai.org/symbols/NASDAQ-AZTA), [NASDAQ:RGEN](https://stocks.freetheai.org/symbols/NASDAQ-RGEN)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Shares of several healthcare and biotechnology companies dropped sharply during afternoon trading as rising Treasury yields prompted a broader market shift away from high-risk growth equities. Pacific Biosciences of California, Inc. (NASDAQ:PACB), Moderna, Inc. (NASDAQ:MRNA), Myriad Genetics, Inc. (NASDAQ:MYGN), Azenta, Inc. (NASDAQ:AZTA), and Repligen Corporation (NASDAQ:RGEN) all experienced price declines.

Higher interest rates directly impact long-duration assets by increasing the discount rates applied to projected future earnings. This reduces the present value of expected cash flows, which is particularly challenging for clinical-stage healthcare and drug development firms that depend on distant profits and frequent debt financing to fund ongoing research and development. In response, capital moved out of high-multiple healthcare assets toward government bonds and large-cap stocks.

Investors will be watching how these capital-intensive companies manage borrowing costs and research budgets if interest rates remain elevated. For Pacific Biosciences of California, Inc. (NASDAQ:PACB), which has experienced 86 stock moves over 5% in the past year, market attention will focus on whether upcoming business milestones and genomics partnerships can stabilize valuation amid persistent macroeconomic pressure.

## Key points

- Rising Treasury yields led to a sell-off in capital-intensive growth and life sciences equities.
- Higher interest rates elevate discount rates on future earnings, lowering present valuations for early-stage healthcare firms.
- Pacific Biosciences of California, Inc. (NASDAQ:PACB) fell over 11% during the trading session.
- Moderna, Inc. (NASDAQ:MRNA), Myriad Genetics, Inc. (NASDAQ:MYGN), Azenta, Inc. (NASDAQ:AZTA), and Repligen Corporation (NASDAQ:RGEN) also declined.

## Questions and answers

### Why did healthcare and biotechnology stocks fall?

Elevated Treasury yields increased discount rates applied to future corporate earnings, reducing valuations for capital-intensive healthcare companies relying on future cash flows and debt funding.

### Which stocks were affected by the market sell-off?

Declining stocks included Pacific Biosciences of California, Inc. (NASDAQ:PACB), Moderna, Inc. (NASDAQ:MRNA), Myriad Genetics, Inc. (NASDAQ:MYGN), Azenta, Inc. (NASDAQ:AZTA), and Repligen Corporation (NASDAQ:RGEN).

### How do rising interest rates impact clinical-stage drug companies?

Higher interest rates raise borrowing costs and debt-servicing expenses, making it more expensive for clinical-stage healthcare firms to access debt markets and fund research and development.